Pharmaceuticals, Biotechnology and Life Sciences
Phase 2/3 trial (EBO-301) in treatment-refractory Mycobacterium avium Complex (TR-MAC) continues with Phase 2 topline results expected in summer 2024…
CINCINNATI–(BUSINESS WIRE)–Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its first quarter 2024 financial results after…
PRINCETON, N.J.–(BUSINESS WIRE)–$BMY #KRAZATI— Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free…
– Celebrating Amneal’s recent listing on the Nasdaq Stock Exchange BRIDGEWATER, N.J.–(BUSINESS WIRE)–Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the…
Topline data for Phase 3 RINGSIDE trial of AL102 expected in first quarter of 2025 IM-1021 and IM-3050 IND filings…
PRINCETON, N.J.–(BUSINESS WIRE)–$BMY #Crohns—Bristol Myers Squibb (NYSE: BMY) today announced an update following the initial analysis of results from the…
Company recognizes significant support by board members in recent private placement CHICAGO–(BUSINESS WIRE)–MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the…
DUBLIN–(BUSINESS WIRE)–The “Long-Acting Drug Delivery Technologies and Services Market: A Global and Regional Analysis, 2023-2033” report has been added to…
The DSMB, based on Phase 3 trial ARES preliminary data, concluded that MaaT013 has a favorable benefit/risk ratio with “high…
Company Funded by Kaleida Capital, Atma Capital, Connecticut Innovations and angel investors NAIO™ (Neuroscience and Artificial Intelligence Optimized) technology platform,…